Pharma stock jumps 9% after signing $11.75 Bil deal to acquire US-based firm
Synopsis:- Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon & Co. for $14 per share in an all-cash deal worth $11.75 billion in enterprise value, a transaction that vaults India’s largest pharma company into the global top-25 by revenue and the top-3 in women’s health. The deal closes the biosimilar gap Sun Pharma never filled organically, but Organon’s $8.6 billion debt load is the number that demands attention.
In one of India’s biggest-ever outbound deals, the country’s largest pharmaceutical company has signed a definitive agreement to acquire NYSE-listed Organon & Co.the New Jersey-based firm specializing in women’s health, biosimilars, and established brands across 140+ countries in a fully cash-funded transaction.
With a market capitalization of Rs. 4,15,757 crore, the shares of Sun Pharmaceutical Industries Limited were trading at Rs. 1,766.15 per share as of April 27, 2026, up by 9 percent from its previous closing price of Rs. 1,620.45. It is trading at a P/E of 34.2.
What Does Sun Get from This Deal?
Organon isn’t just another acquisition target. The Merck spinoff, founded in 2020, brings a commercially rich portfolio spanning over 70 products across women’s health, biosimilars, and established branded medicines sold across 140+ countries. Its women’s health franchise alone, ranked #2 in contraceptives and #3 in fertility globally, gives Sun an entirely new therapeutic pillar it currently lacks.
The deal catapults the combined entity into the top 25 global pharma companies, with a pro-forma revenue of approximately $12.4 billion. Sun’s innovative medicines revenue share rises from 20% to 27%, and the combined biosimilars business lands them at 7th globally in that fast-growing segment. Perhaps most compelling is the scale leap: from 100+ countries to 150 markets, with 18 of them generating over $100 million each in revenue.
Financially, both EBITDA and free cash flows are projected to roughly double post-merger, with combined EBITDA reaching $3.7 billion and free cash flows hitting $2.5 billion before financing. Sun also sees over $350 million in potential synergies within two to four years, driven by cross-portfolio commercialization, Sun’s branded generics playbook applied to Organon’s established brands, and cost efficiencies.
The Elephant in the Room: Organon’s Debt
Here’s where investors need to pause. Organon carries a significant debt burden of $8.6 billion against a cash balance of just $574 million as of December 2025. The deal’s enterprise value of $11.75 billion factors in this debt load, which means Sun is effectively absorbing a heavily leveraged business.
Post-transaction, the combined Net Debt/EBITDA ratio is estimated at approximately 2.3x, a meaningful step down from Organon’s standalone 4.0x, but still a number Sun’s currently net-cash balance sheet has never had to manage. Sun plans to fund the deal using $2–2.5 billion of its own cash and $9.25–9.75 billion in committed bank financing, bringing in lenders including JPMorgan, Citigroup, and MUFG.
Integrating two companies of this scale with different cultures, geographies, and portfolio DNA adds further execution risk. Organon’s revenue has also been essentially flat over the past three years ($6.26 billion in 2023, $6.4 billion in 2024, and $6.2 billion in 2025), raising questions about near-term organic growth momentum.
Detailed investor overview
Sun Pharma’s acquisition of Organon is less a diversification move and more a structural leap, one that compresses a decade of organic buildout into a single transaction. Before this deal, Sun Pharma had no meaningful biosimilar presence and limited women’s health scale globally. Organon fixes both instantly. The combined $12.4 billion revenue base places the merged entity among the world’s top-25 pharma companies, while the top-3 position in global women’s health creates a durable commercial platform that few Indian peers can claim.
Innovative medicines now account for 27% of combined revenues, a mix that commands better valuation multiples over time. The growth lever, however, is integration. Organon’s revenue has been flat for three years, meaning incremental growth must come from Sun Pharma’s commercial engine layered onto Organon’s global footprint, particularly in emerging markets where Sun Pharma already has deep relationships. If that cross-sell materializes, the 2.3x post-deal leverage unwinds faster than guided. If it doesn’t, the $8.6 billion debt becomes the story.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
